Cost Analysis for the Prevention of Variceal Rebleeding: A Comparison Between Transjugular Intrahepatic Portosystemic Shunt and Endoscopic Sclerotherapy in A Selected Group of Italian Cirrhotic Patients
- 1 April 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 29 (4) , 1074-1077
- https://doi.org/10.1002/hep.510290411
Abstract
The aim of the present study was to compare the cumulative cost of the first 18–month period in a selected group of Italian cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic sclerotherapy (ES) to prevent variceal rebleeding. Thirty–eight patients enrolled in a controlled trial were considered (18 TIPS and 20 sclerotherapy). The number of days spent in the hospital for the initial treatment and during the follow–up period were defined as the costs of hospitalization. ES sessions, TIPS procedures, angioplasty or addition of a second stent to maintain the shunt patency, were defined as the costs of therapeutic procedures. The two groups were comparable for age, sex, and Child–Pugh score. During the observation period 4 patients died in the TIPS group, and 2 died and 1 was transplanted in the sclerotherapy group. The rebleeding rate was significantly higher in the sclerotherapy group. Despite this, the number of days spent in the hospital was similar in the two groups. This was because of a higher number of hospital admissions for the treatment of hepatic encephalopathy and shunt insufficiency in the TIPS group. The therapeutic procedures were more expensive for TIPS. Consequently, the cumulative cost was higher for patients treated with TIPS than for those treated with sclerotherapy. The extra cost was because of the initial higher cost of the procedure and the difference was still maintained at the end of the 18–month follow–up. When the cumulative costs were expressed per month free of rebleeding, the disadvantage of TIPS disappeared. In conclusion, a program of prevention of variceal rebleeding with TIPS, despite the longer interval free of rebleeding, is not a cost–saving strategy in comparison with sclerotherapyKeywords
This publication has 14 references indexed in Scilit:
- Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trialHepatology, 1998
- Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleedingGastroenterology, 1997
- Endoscopic Sclerotherapy Compared with Percutaneous Transjugular Intrahepatic Portosystemic Shunt after Initial Sclerotherapy in Patients with Acute Variceal HemorrhageAnnals of Internal Medicine, 1997
- Transjugular Intrahepatic Portosystemic Shunts Compared with Endoscopic Sclerotherapy for the Prevention of Recurrent Variceal HemorrhageAnnals of Internal Medicine, 1997
- Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleedingThe Lancet, 1997
- Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trialJournal of Hepatology, 1996
- Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhageGastroenterology, 1996
- The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory boardHepatology, 1995
- Impact of Shunt Surgery for Variceal Bleeding in the Natural History of Ascites in Cirrhosis: A Retrospective StudyHepatology, 1994
- The Transjugular Intrahepatic Portosystemic Stent-Shunt Procedure for Variceal BleedingNew England Journal of Medicine, 1994